
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst is a profitable company with strong recurring revenue and a potential acquisition market for its applications, evidenced by the success of its peer company Premier last year. This, combined with a conservative 2x revenue multiple, indicates the potential for Health Catalyst to generate significant proceeds from its applications segment, possibly nearing $100 million.
Bears say
Health Catalyst is facing pressure as their core data infrastructure platform is underperforming, causing a disappointing outlook for revenues and EBITDA. This is intensified by the lack of annual guidance due to ongoing strategic and operational reviews and a recent CEO transition. However, there may be opportunities for the company to create shareholder value through divesting certain attractive app layer assets or potentially selling the entire company. Additionally, monetizing assets such as VitalWare could provide a way out of the current situation and allow the company to focus on growth in the insights and apps layer.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares